NEW YORK (GenomeWeb News) – Caprotec Bioanalytics announced today that it has received a total of €6 million ($8.8 million) from two rounds of private financing to support further development and marketing of the firm’s Capture Compound Mass Spectrometry technology for analyzing complex protein mixtures.
Investors in the two rounds included Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and private investors including Heinrich-Maria Schulte, co-founder of Evotec and owner of the Wölbern Bank in Hamburg, Germany.
According to Berlin-based Caprotec, the CCMS technology enables targeted isolation of proteins or protein classes directly from a complex biological sample. The captured proteins are then identified and characterized by mass spectrometry.
“Our platform closes a technological gap in the field of proteome analysis with its ability to be applied in both water-soluble and membrane protein mixtures,” said Caprotec CEO and Founder Hubert Köster.